Tetanus, diphtheria, and pertussis are three serious bacterial diseases that were once common causes of severe illness and death. Today, routine immunization has dramatically reduced their incidence, but these infections continue to pose a threat—particularly to infants, older adults, and individuals who are not fully vaccinated.

Vaccination remains the most effective way to prevent these potentially life-threatening diseases.

Disease Comparison & Clinical Overview

Understanding the key differences in transmission, pathology, and clinical presentation is essential for prompt recognition and prevention.

Disease	Causative Pathogen	Transmission	Key Clinical Features	High-Risk Groups & Prognosis
Tetanus (“Lockjaw”)	Clostridium tetani (Gram-positive, anaerobic, spore-forming)	Not person-to-person. Spores enter via deep/contaminated wounds (soil, manure).	Jaw stiffness, painful muscle spasms, trismus, generalized rigidity, dysphagia.	Adults >50 years. ≥10% mortality rate even with medical care.
Diphtheria	Corynebacterium diphtheriae (Gram-positive bacillus)	Respiratory droplets or direct contact with skin lesions.	Pseudomembranous pharyngitis (thick gray throat membrane), severe sore throat, airway obstruction.	Unvaccinated individuals. Extremely rare in US (>10 years with no cases).
Pertussis (Whooping Cough)	Bordetella pertussis (Gram-negative bacterium)	Respiratory droplets (coughing/sneezing). Highly contagious.	Catarrhal stage (cold-like) → Paroxysmal stage (violent cough bursts, “whoop”, post-tussive vomiting).	Infants <1 year (risk of pneumonia, seizures, brain injury, death). Requires >90% herd immunity.

Deep-Dive: Disease Dynamics

Tetanus Pathogenesis

Infection occurs when bacterial spores enter anaerobic wound environments. The proliferating bacteria release a potent neurotoxin that binds peripheral motor nerve terminals, traveling to the central nervous system to cause unabated muscular contraction.

Pertussis Clinical Progression

Pertussis progresses through two primary clinical stages following an incubation period of 1 to 3 weeks:

• Catarrhal Phase (Weeks 1–2): Mild upper respiratory symptoms including rhinorrhea, nasal congestion, sneezing, low-grade fever, and mild cough. Highly contagious stage.
• Paroxysmal Phase (Weeks 2–6+): Paroxysms of rapid, violent coughing followed by a high-pitched inspiratory “whoop,” post-tussive emesis, cyanosis, and exhaustion.

Vaccine Formulations & Lifetime Administration Schedules

Vaccine selection depends directly on recipient age and vaccination history due to differing component concentrations (d/D and p/P levels).

Vaccine	Components	Target Population	Recommended Schedule
DTaP	Full-dose Diphtheria, Tetanus, & Acellular Pertussis	Infants & Children (2 months – 6 years)	5-Dose Childhood Series: • 2 months, 4 months, 6 months • 15–18 months • 4–6 years
Tdap	Tetanus, Reduced-dose Diphtheria, Acellular Pertussis	Adolescents, Adults, & Pregnant Persons	• Adolescents: Single booster at 11–12 years • Adults: 1 dose if never received, then booster every 10 years • Pregnancy: 1 dose during every pregnancy (27–36 weeks preferred)
Td	Tetanus & Reduced-dose Diphtheria (No pertussis)	Adults (≥7 years)	Routine adult booster every 10 years (interchangeable with Tdap).

Adult Primary Series (Unvaccinated)

Adults with no prior immunization require a 3-dose primary series:

• Dose 1: Tdap
• Dose 2: Td or Tdap (at least 4 weeks after Dose 1)
• Dose 3: Td or Tdap (6–12 months after Dose 2)
• Followed by boosters every 10 years.

Post-Exposure & Prophylaxis Protocols

Specific guidelines govern management following injury or direct exposure to prevent disease outbreak.

1. Tetanus Wound Management Algorithm

Vaccination History	Clean, Minor Wounds	Dirty or High-Risk Wounds (Deep, soil/manure, puncture)
Uncertain or <3 Doses	Vaccine (Td or Tdap) (No TIG needed)	Vaccine (Td or Tdap) PLUS Tetanus Immune Globulin (TIG)
≥3 Primary Doses	Vaccine only if last dose was >10 years ago	Vaccine only if last dose was >5 years ago (No TIG needed)

2. Pertussis Post-Exposure Management

• Vaccination: Administer age-appropriate DTaP or Tdap to any exposed individual who is unvaccinated or under-vaccinated.
• Post-Exposure Antimicrobial Prophylaxis (PEP): Recommended for all household contacts and contacts at high risk for severe disease (infants, 3rd-trimester pregnant women, immunocompromised individuals, asthmatics).
• First-line Antibiotics: Macrolides (e.g., azithromycin, clarithromycin, erythromycin) or Trimethoprim-sulfamethoxazole (TMP-SMX).

3. Diphtheria Post-Exposure Management

• Vaccination: Immediate diphtheria-containing booster for close contacts if not vaccinated within the past 5 years.
• Antimicrobial Prophylaxis: All close contacts should receive preventive antibiotics regardless of vaccination status:
  • Single IM injection of Benzathine penicillin G, OR
  • Oral Erythromycin for 7 to 10 days.